NOT-DA-20-044: Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)

Notice Number: NOT-DA-20-044

Key Dates
Release Date: March 17, 2020
Estimated Publication Date of Funding Opportunity Announcement: May 01, 2020
First Estimated Application Due Date: July 13, 2020
Earliest Estimated Award Date: April 01, 2021
Earliest Estimated Start Date: April 01, 2021

Related Announcements
RFA-DA-18-019

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to reissue the Funding Opportunity Announcement (FOA) RFA-DA-20-019, "NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)." When reissued, this FOA will continue to utilize the DP1 mechanism.

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term avant-garde refers to highly innovative ideas and/or approaches that have the potential to be transformative. Applications responding to this FOA must propose research that aligns with the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in May 2020 with an expected application due date in July 2020.

Ressearch Initiative Details

The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV/AIDS; creative, new strategies to prevent HIV transmission; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches to eradicating HIV or improving the lives of PWUD living with HIV.

Applications responding to this FOA must clearly describe the nexus with Substance Use Disorders and have to substantially differ from what is currently being pursued by the investigator or others in the relevant research area.

Funding Information

Expected Number of Awards: NIDA intends to fund a maximum of four awards.

Estimated Award Ceiling: Application budgets are limited to $700,000 in direct costs per year.

Primary CFDA Numbers: 93.279

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Independent school districts
County governments
Indian/Native American Tribal Government (Federally Recognized)
State Government
For-Profit Organization (Other than Small Business)
Small Business
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Private Institution of Higher Education
Regional Organization
Non-domestic (non-U.S.) Entity (Foreign Organization)
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Redonna Chandler, Ph.D.
National Institute on Drug Abuse (NIDA)
301-402-1919
rchandle@nida.nih.gov

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov